Ameliorating post-infarction myocardial fibrosis and cardiac function via ROS-responsive hydrogel-mediated IL-11 antibody delivery.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 41674553.
- Also identified by DOI 10.1016/j.bioactmat.2026.01.041 and PMC identifier 12887659.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Myocardial fibrosis, driven by fibroblast activation following myocardial infarction (MI), represents a significant pathological process contributing to heart failure progression. Interleukin-11 (IL-11) is recognized as a key mediator in fibrotic pathologies across multiple organs, including the heart. This study demonstrates consistent and specific upregulation of IL-11 expression in a mouse MI model. A single intrapericardial injection of the IL-11-blocking antibody hIL-11 MAB resulted in a modest attenuation of post-MI fibrosis. Subsequently, encapsulation of hIL-11 MAB within reactive oxygen species (ROS)-sensitive hydrogels significantly prolonged drug retention at the injury site, leading to markedly improved therapeutic efficacy. Hydrogel-delivered hIL-11 MAB effectively preserved cardiac structure and function by reducing scar fibrosis, specifically decreasing scar thickness and marginal zone area. IL-11 blockade mediated reduced collagen deposition and enhanced left ventricular contractility, concomitant with a decrease in fibrotic tissue stiffness. These findings provide compelling evidence supporting IL-11 as a therapeutic target for myocardial fibrosis and highlight a novel delivery strategy for developing improved anti-fibrotic interventions.